LookAHEAD: Look AHEAD: Action for Health in Diabetes

Sponsor
Wake Forest University Health Sciences (Other)
Overall Status
Completed
CT.gov ID
NCT00017953
Collaborator
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (NIH), National Heart, Lung, and Blood Institute (NHLBI) (NIH), National Institute of Nursing Research (NINR) (NIH), National Institute on Minority Health and Health Disparities (NIMHD) (NIH), Office of Research on Women's Health (ORWH) (NIH), Centers for Disease Control and Prevention (U.S. Fed)
5,145
18
2
229
285.8
1.2

Study Details

Study Description

Brief Summary

The Look AHEAD study is a multi-center, randomized clinical trial to examine the long-term effects of a lifestyle intervention designed to achieve and maintain weight loss. The study will investigate the effects of the intervention on heart attacks, stroke and cardiovascular-related death in individuals with type 2 diabetes who are also overweight or obese.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Lifestyle Intervention
  • Behavioral: Diabetes Support and Education
N/A

Detailed Description

Look AHEAD is examining, in overweight volunteers with type 2 diabetes, the long-term effects of an intensive lifestyle intervention program designed to achieve and maintain weight loss by decreased caloric intake and increased physical activity. This program will be compared to a control condition involving a program of diabetes support and education.

The primary hypothesis is that the incidence rate of the first post-randomization occurrence of a composite outcome, which includes

cardiovascular death (including fatal myocardial infarction and stroke), non-fatal myocardial infarction, hospitalized angina, and non-fatal stroke,

over a planned follow-up period of up to 13.5 years will be reduced among participants assigned to the Lifestyle Intervention compared to those assigned to the control condition, Diabetes Support and Education.

Look AHEAD will also test for reductions in the incidence of three secondary composite outcomes and examine the effect of the intervention on cardiovascular disease risk factors, diabetes control and complications, general health, and quality of life, and psychological outcomes. The cost and cost-effectiveness of the Lifestyle Intervention relative to Diabetes Support and Education will be assessed.

The Look AHEAD intensive lifestyle intervention ended September, 2012. Participants continue to be followed to determine the long-term effects of the intervention on health outcomes.

Study Design

Study Type:
Interventional
Actual Enrollment :
5145 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Look AHEAD: Action for Health in Diabetes
Actual Study Start Date :
Jun 1, 2001
Actual Primary Completion Date :
Sep 1, 2012
Actual Study Completion Date :
Jun 30, 2020

Arms and Interventions

Arm Intervention/Treatment
Experimental: Lifestyle Intervention

Participants in the lifestyle intervention arm are offered individual and group sessions designed to help achieve and maintain weight loss.

Behavioral: Lifestyle Intervention
The lifestyle intervention is implemented with individual supervision and group sessions and is aimed at achieving and maintaining at least a 7% decrease in weight from baseline and 175 minutes per week in physical activity. It is implemented during a four-year period with the most intensive application during the first year, less frequent attention during the next three years, and a minimum of twice yearly contacts during an extended follow-up period. To help participants achieve and maintain weight loss, a variety of diet strategies (e.g. prepared meals and liquid formula), exercise strategies, and optional weight loss medications are utilized based on a preset algorithm and participant progress.

Active Comparator: Diabetes Support and Education

The diabetes support and education arm provides group sessions on diabetes management and social support.

Behavioral: Diabetes Support and Education
Participants assigned to diabetes support and education are offered three sessions each year in diabetes management and social support.

Outcome Measures

Primary Outcome Measures

  1. Aggregate occurrence of severe cardiovascular events. [up to 11 years]

    Aggregate occurrence of major cardiovascular events including fatal and non-fatal myocardial infarctions and strokes, hospitalizations for angina, and cardiovascular deaths

Secondary Outcome Measures

  1. Secondary aggregate events #1 [up to 11 years]

    Aggregate occurrence of cardiovascular deaths, myocardial infarctions (fatal or nonfatal), and strokes (fatal or non-fatal)

  2. Secondary aggregate events #2 [up to 11 years]

    Aggregate occurrence of deaths (all causes), myocardial infarctions, strokes, and hospitalizations for angina;

  3. Secondary aggregate events #3 [up to 11 years]

    Aggregate occurrence of deaths (all causes), myocardial infarctions, strokes, hospitalizations for angina, coronary artery bypass graftings, percutaneous coronary angioplasty, hospitalizations for congestive heart failure, carotid endarterectomies, or peripheral vascular procedures such as bypass or angioplasty

  4. Aggregate occurrence of severe cardiovascular events for up to 20 years [up to 20 years]

    Aggregate occurrence of major cardiovascular events including fatal and non-fatal myocardial infarctions and strokes, hospitalizations for angina, and cardiovascular deaths

  5. Change in Short Form 36 (SF-36) Physical Score [Baseline and annually for up to 11 years, exams 1 (16-18 years) and 2 (18-20 years)]

    Scores range from 0 to 100, with a higher score representing a higher level of functioning.

  6. Frailty [Exams 1 (16-18 years) and 2 (18-20 years)]

    Frailty is assessed using the Fried criteria and is classified as non-frail, pre-frail, or frail

  7. End stage renal disease (ESRD) [up to 20 years]

    ESRD is defined as renal replacement therapy (RRT) or death from nephropathy

Eligibility Criteria

Criteria

Ages Eligible for Study:
55 Years to 76 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Type 2 diabetes

  • Overweight

  • BMI of 25 kg/m2 or greater

  • If on insulin, BMI of 27 kg/m2 or greater

  • Blood pressure less than 160/100 mmHg

  • HbA1c less or equal to 11%

  • Triglycerides less than 600 mg/dl

  • Willingness to participate

Exclusion Criteria:
  • Unable or unwilling to give informed consent or communicate with local study staff.

  • Current diagnosis of schizophrenia, other psychotic disorders, or bipolar disorder.

  • Hospitalization for depression in past six months.

  • Self-report of alcohol or substance abuse within the past twelve months.

  • Current consumption of more than 14 alcoholic drinks per week.

  • Current acute treatment or rehabilitation program for these problems.

  • Plans to relocate to an area not served by Look AHEAD or travel plans that do not permit full participation in the study.

  • Lack of support from primary care health provider or family members.

  • Failure to complete the two-week run-in for dietary intake and exercise.

  • Weight loss exceeding 10 lbs. in past three months.

  • Current use of medications for weight loss.

  • Self reported inability to walk two blocks.

  • History of bariatric surgery, small bowel resection, or extensive bowel resection.

  • Chronic treatment with systemic corticosteroids.

  • Another member of the household is a participant or staff member in Look AHEAD.

  • Currently pregnant or nursing.

  • Cancer requiring treatment in the past five years, except for non-melanoma skin cancers or cancers that have clearly been cured.

  • HIV positive (self-report), due to effects on weight and body composition of HIV and medications used to treat HIV.

  • Active tuberculosis (self-report).

  • Cardiovascular disease (heart attack or procedure within the past three months).

  • Participation in a cardiac rehabilitation program within last three months.

  • Stroke or history/treatment for transient ischemic attacks in the past three months.

  • Pulmonary embolus in past six months.

  • Unstable angina pectoris or angina pectoris at rest.

  • A history of cardiac arrest.

  • Complex ventricular arrhythmia at rest or with exercise (e.g., ventricular tachycardia).

  • Uncontrolled atrial fibrillation (heart rate of 100 beats per minute or more).

  • New York Heart Association (NYHA) Class III or IV congestive heart failure.

  • Acute myocarditis, pericarditis or hypertrophic myocardiopathy.

  • Clinically significant aortic stenosis.

  • Left bundle branch block or cardiac pacemaker unless evaluated and cleared for participation by a cardiologist.

  • Cardiac defibrillator.

  • Heart transplant.

  • History of aortic aneurysm of at least 7 cm in diameter or aortic aneurysm repair.

  • Resting heart rate less than 45 beats per minute or greater than 100 beats per minute.

  • Any abnormality during the maximum exercise stress test that indicates that it would be unsafe to participate in the Lifestyle Intervention.

  • Angina pectoris.

  • Significant ST segment depression at low levels of exercise.

  • Exercise induced ventricular arrhythmias.

  • Abnormal hemodynamics, such as flat or decreasing systolic blood pressure with increasing workload.

  • Those at moderate to high risk for cardiac complications during exercise.

  • Those who are unable to self-regulate activity or understand the recommended activity level.

  • Renal disease or dialysis.

  • Chronic obstructive pulmonary disease that would limit ability to follow the protocol.

  • Self-reported chronic hepatitis B or C or cirrhosis.

  • Inflammatory bowel disease requiring treatment in past year.

  • Cushing's syndrome.

  • Acromegaly.

  • Amputation of lower limbs as result of non-traumatic causes.

  • Any major organ transplant.

Contacts and Locations

Locations

Site City State Country Postal Code
1 The University of Alabama at Birmingham Birmingham Alabama United States 35205
2 Southwestern American Indian Center Phoenix Arizona United States 85014
3 University of Southern California Los Angeles California United States 90022
4 University of Colorado Health Sciences Center Aurora Colorado United States 80045-0808
5 Louisiana State University Baton Rouge Louisiana United States 70808
6 Johns Hopkins Pro-Health Baltimore Maryland United States 21207
7 Diabetes Center Boston Massachusetts United States 02114
8 Joslin Diabetes Center Boston Massachusetts United States 02114
9 University of Minnesota Minneapolis Minnesota United States 55415-1226
10 Northern Navajo Medical Center Shiprock New Mexico United States 87420
11 Columbia University New York New York United States 10019
12 University of Pennsylvania Medical Center Philadelphia Pennsylvania United States 19104
13 University of Pittsburgh Pittsburgh Pennsylvania United States 15213
14 The Miriam Hospital Providence Rhode Island United States 02906
15 The University of Tennessee, Memphis Memphis Tennessee United States 38105
16 Baylor College of Medicine Houston Texas United States 77030
17 University of Texas Health Sciences Center San Antonio Texas United States 78229
18 University of Washington Seattle Washington United States 98108

Sponsors and Collaborators

  • Wake Forest University Health Sciences
  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
  • National Heart, Lung, and Blood Institute (NHLBI)
  • National Institute of Nursing Research (NINR)
  • National Institute on Minority Health and Health Disparities (NIMHD)
  • Office of Research on Women's Health (ORWH)
  • Centers for Disease Control and Prevention

Investigators

  • Principal Investigator: Mark A Espeland, PhD, Wake Forest University Health Sciences

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Wake Forest University Health Sciences
ClinicalTrials.gov Identifier:
NCT00017953
Other Study ID Numbers:
  • BG99-042
  • U01DK057136
  • U01DK057149
  • U01DK056990
  • U01DK057177
  • U01DK057171
  • U01DK057151
  • U01DK057182
  • U01DK057131
  • U01DK057002
  • U01DK057078
  • U01DK057154
  • U01DK057178
  • U01DK057219
  • U01DK057008
  • U01DK057135
  • U01DK056992
  • NCT00000624
First Posted:
Jun 21, 2001
Last Update Posted:
Feb 22, 2022
Last Verified:
Feb 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Wake Forest University Health Sciences
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 22, 2022